TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36170550

Group type: COMPARATOR
Intervention: Exercise alone
Number of subjects: 318

Group type: COMPARATOR
Intervention: Weight loss alone
Number of subjects: 318

Group type: COMPARATOR
Intervention: Exercise plus weight loss
Number of subjects: 318

Group type: COMPARATOR
Intervention: Weight loss alone (among participants with elevated CRP at baseline)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Exercise plus weight loss (among participants with elevated CRP at baseline)
Number of subjects: 318
Study: 33626197

Group type: EXPERIMENTAL
Intervention: FLUGA (fludarabine, cytarabine, and filgrastim)
Number of subjects: 283

Group type: COMPARATOR
Intervention: AZA (azacitidine)
Number of subjects: 283
Study: 32726200

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 seropositivity testing
Number of subjects: 1075
Study: 34308678

Group type: EXPERIMENTAL
Intervention: Local heat therapy
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Cold rub gel
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 117
Study: 33404695

Group type: EXPERIMENTAL
Intervention: Low monoenergetic DECT images
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional DECT images
Number of subjects: 50
Study: 36099876

Group type: EXPERIMENTAL
Intervention: 5-Aminolevulinic Acid with Sodium Ferrous Citrate (5-ALA + SFC)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 34015020

Group type: EXPERIMENTAL
Intervention: Machine learning prediction model for waiting time to kidney transplant
Number of subjects: 48153

Group type: COMPARATOR
Intervention: Cox regression model
Number of subjects: 48153
Study: 32690050

Group type: EXPERIMENTAL
Intervention: High personal relevance: personal autobiographical photographs
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Medium personal relevance: pictures of favourite locations associated with specific positive autobiographical memories
Number of subjects: 240

Group type: COMPARATOR
Intervention: Low personal relevance: positive images from the International Affective Picture System
Number of subjects: 240
Study: 36084714

Group type: EXPERIMENTAL
Intervention: Partially Covered Double Bare Self-expandable Metal Stent (PCDBS)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Uncovered Double Bare Self-expandable Metal Stent (UCDBS)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Chemotherapy after stent placement
Number of subjects: 258
Study: 33675226

Group type: EXPERIMENTAL
Intervention: liquid MVA given subcutaneously (liquid-SC group)
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: liquid MVA given intradermally (liquid-ID group)
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: lyophilized MVA given subcutaneously
Number of subjects: 523

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 523
Study: 32176092

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine Shenqi Compound
Number of subjects: 60

Group type: COMPARATOR
Intervention: Basic treatment combined with Chinese medicine placebo
Number of subjects: 60
Study: 33563012

Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Medical management (MM)
Number of subjects: 182
Study: 36286839

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once a day
Number of subjects: 4304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4304
Study: 35947804

Group type: EXPERIMENTAL
Intervention: lenalidomide plus rituximab (R2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rituximab plus chemotherapy (R-chemo)
Number of subjects: 0
Study: 33588801

Group type: EXPERIMENTAL
Intervention: Prophylactic metformin 500 mg twice daily for 72 hours
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 34532888

Group type: EXPERIMENTAL
Intervention: Itraconazole 100 mg/day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg/day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Itraconazole 400 mg/day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Itraconazole (all doses)
Number of subjects: 40
Study: 33226907

Group type: COMPARATOR
Intervention: Low-fidelity ceramic tile model
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Mid-fidelity 3D printed canine skull model
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High-fidelity canine head model
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: All models
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 3D skull and full head models
Number of subjects: 36
Study: 36468403

Group type: EXPERIMENTAL
Intervention: Active BP lowering treatment (combination perindopril±indapamide)
Number of subjects: 10885
Study: 33476415

Group type: EXPERIMENTAL
Intervention: Oral sulfate solution same-day dose (n=200)
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Oral sulfate solution split-dose (n=202)
Number of subjects: 602

Group type: COMPARATOR
Intervention: Polyethylene glycol plus ascorbate (n=200)
Number of subjects: 602
Study: 36484364

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (3 times per week during irradiation, diode laser: 660 nm, 75 mW, 1.5 cm2, 50 mW/cm2, 60 seconds exposure, 3 J/cm2, 20-30 spots per session)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Sham low-level laser therapy (identical delivery method to low-level laser therapy)
Number of subjects: 87
Study: 33639454

Group type: EXPERIMENTAL
Intervention: Kegel exercises
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no Kegel exercises)
Number of subjects: 60
Study: 32784153

Group type: EXPERIMENTAL
Intervention: Loaded Dix-Hallpike (L-DH)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard Dix-Hallpike (S-DH)
Number of subjects: 28
Study: 36111892

Group type: EXPERIMENTAL
Intervention: trCTCs positive patients
Number of subjects: 33

Group type: COMPARATOR
Intervention: trCTCs negative patients
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: trCTCs positivity
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 1-year postoperative trCTCs positivity
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Integrating clinicopathological features with trCTCs
Number of subjects: 33
Study: 36317751

Group type: EXPERIMENTAL
Intervention: SHR4640 (10 mg) under fed conditions
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: SHR4640 (10 mg) under fasted conditions
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: SHR4640 (10 mg)
Number of subjects: 14
Study: 33753349

Group type: EXPERIMENTAL
Intervention: Telemedicine IMPACT Plus intervention (multi-provider case conference with follow-up)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 163
Study: 32853584

Group type: EXPERIMENTAL
Intervention: Eltrombopag 50 mg orally daily from 21 days preoperatively to postoperative day 7
Number of subjects: 74

Group type: COMPARATOR
Intervention: Intravenous immunoglobulin 1 g/kg or 2 g/kg 7 days before surgery
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Eltrombopag (per-protocol analysis)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Intravenous immunoglobulin (per-protocol analysis)
Number of subjects: 74
Study: 35768027

Group type: EXPERIMENTAL
Intervention: Treatment received aligned with recommendations
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Discordant treatment recommendations
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Urologists' and radiation oncologists' treatment recommendations
Number of subjects: 108
Study: 32464351

Group type: EXPERIMENTAL
Intervention: 50 mg of 5-Hydroxytryptophan (5-HTP) daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 35229404

Group type: EXPERIMENTAL
Intervention: EQ-5D-5L
Number of subjects: 0

Group type: COMPARATOR
Intervention: EQ-5D-3L
Number of subjects: 0
Study: 34727839

Group type: EXPERIMENTAL
Intervention: Individual SDOH variables (fewer years of education, lower income)
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Community SDOH (lower rates of health insurance, lower income, greater income inequality)
Number of subjects: 664
Study: 35176190

Group type: EXPERIMENTAL
Intervention: Sodium propionate (SP) supplementation for 12 weeks
Number of subjects: 32
Study: 34521208

Group type: EXPERIMENTAL
Intervention: Individual placement and support (IPS) (N=58)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Standard VHA non‐IPS vocational rehabilitation (VR) (N=61)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: IPS
Number of subjects: 119
Study: 35683586

Group type: EXPERIMENTAL
Intervention: Core training program (six weeks, three times/week) with regular swimming training
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Core training program
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (regular training)
Number of subjects: 18
Study: 32600474

Group type: EXPERIMENTAL
Intervention: Choledochojejunostomy
Number of subjects: 210

Group type: COMPARATOR
Intervention: T-tube drainage
Number of subjects: 210
Study: 33990951

Group type: EXPERIMENTAL
Intervention: Lasmiditan 200 mg
Number of subjects: 846

Group type: EXPERIMENTAL
Intervention: Lasmiditan 100 mg
Number of subjects: 846

Group type: EXPERIMENTAL
Intervention: Lasmiditan 50 mg
Number of subjects: 846

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 846
Study: 34727753

Group type: EXPERIMENTAL
Intervention: Choice awareness communication present
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Physician preference communication present
Number of subjects: 684

Group type: COMPARATOR
Intervention: Choice awareness communication absent
Number of subjects: 684

Group type: COMPARATOR
Intervention: Physician preference communication absent
Number of subjects: 684
Study: 34666470

Group type: EXPERIMENTAL
Intervention: IONM combined with 'classification of EBSLN' in experimental group
Number of subjects: 827

Group type: COMPARATOR
Intervention: Control group (ligation of branches of the superior thyroid vessels without attempts to visually identify the nerve)
Number of subjects: 827
Study: 32919383

Group type: EXPERIMENTAL
Intervention: Implementation of a multistrategy intervention to improve teachers' implementation of a school physical activity policy
Number of subjects: 1502
Study: 36457123

Group type: EXPERIMENTAL
Intervention: Educational support intervention including peer groups for infant care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34229295

Group type: EXPERIMENTAL
Intervention: Co-morbid insomnia and sleep apnea (COMISA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epidemiological research, case studies, single-arm treatment studies, randomized controlled treatment trials, and objective sleep study data
Number of subjects: 0
Study: 33749219

Group type: EXPERIMENTAL
Intervention: Implants placed freehand by experienced clinicians
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Post-hoc planning versus actual placement
Number of subjects: 77
Study: 33017456

Group type: EXPERIMENTAL
Intervention: 90 g/day low-carbohydrate diet (LCD)
Number of subjects: 92

Group type: COMPARATOR
Intervention: traditional diabetic diet (TDD)
Number of subjects: 92
Study: 33184632

Group type: EXPERIMENTAL
Intervention: Low-fat dairy diet (3.3 servings/d)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Full-fat dairy diet (3.3 servings/d)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Limited dairy diet (≤3 servings/wk of nonfat milk)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Full-fat dairy diet
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Low-fat dairy diet
Number of subjects: 72
Study: 32172599

Group type: EXPERIMENTAL
Intervention: Antiretroviral Therapy (ART) adherence strategies
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: Individual-level strategies to improve adherence
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: Family- or community-level interventions
Number of subjects: 527
Study: 32195538

Group type: EXPERIMENTAL
Intervention: Daily isocaloric meal with standardized amount of avocado (males: 175 g; females: 140 g) for 12 weeks
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Daily isocaloric meal with standardized amount of avocado
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control meals (without avocado)
Number of subjects: 115
Study: 35602971

Group type: EXPERIMENTAL
Intervention: BCAA (30 g, b.i.d. for 21 days)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Microcrystalline cellulose (placebo, 30 g, b.i.d. for 21 days)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Rice protein (placebo, 30 g, b.i.d. for 21 days)
Number of subjects: 32
Study: 35086759

Group type: EXPERIMENTAL
Intervention: FIPELS group (10 patients)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: FIPELS group with palatal speech appliance (10 patients)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional flap design group (10 patients)
Number of subjects: 20
Study: 34391828

Group type: EXPERIMENTAL
Intervention: Statins treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intensive therapy combined with statins
Number of subjects: 0
Study: 32174572

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.1%
Number of subjects: 184

Group type: COMPARATOR
Intervention: Lignocaine 1.0%
Number of subjects: 184
Study: 35105643

Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 68

Group type: COMPARATOR
Intervention: Operative treatment
Number of subjects: 68
Study: 33857412

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks for up to 18 doses
Number of subjects: 1019

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1019

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks for up to 18 doses in PD-L1-positive patients
Number of subjects: 1019

Group type: COMPARATOR
Intervention: Placebo in PD-L1-positive patients
Number of subjects: 1019
Study: 34254461

Group type: EXPERIMENTAL
Intervention: Befriending intervention, paired based on shared interests questionnaire.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (details not specified).
Number of subjects: 16
Study: 33970313

Group type: EXPERIMENTAL
Intervention: 7.5 Fr Uscope PU3033A
Number of subjects: 30

Group type: COMPARATOR
Intervention: 9.5 Fr Uscope PU3022A
Number of subjects: 30
Study: 32100358

Group type: EXPERIMENTAL
Intervention: Oxygenated water
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control water
Number of subjects: 30
Study: 36418068

Group type: EXPERIMENTAL
Intervention: Community Resiliency Model (CRM) intervention, 1-hour virtual class
Number of subjects: 275

Group type: COMPARATOR
Intervention: No treatment control group
Number of subjects: 275
Study: 34455111

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation intervention modeled on MBSR combined with medical group visits (MGV)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Usual PCP care alone
Number of subjects: 450
Study: 36453188

Group type: EXPERIMENTAL
Intervention: Povidone-iodine rectal cleansing
Number of subjects: 552

Group type: COMPARATOR
Intervention: No povidone-iodine rectal cleansing (Control)
Number of subjects: 552
Study: 34247580

Group type: EXPERIMENTAL
Intervention: HMB/Arg/Gln supplementation
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no HMB/Arg/Gln supplementation)
Number of subjects: 38
Study: 35287025

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) administered three times (median, range 1–5 times), with an interval of 9.5 months (mean [SD]) under B cell monitoring.
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) monotherapy, 28 (90%) of 31 patients treated with RTX.
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) administration under B cell monitoring.
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo from the RIN-1 study (control group).
Number of subjects: 38
Study: 32188478

Group type: EXPERIMENTAL
Intervention: DIMS lenses
Number of subjects: 600

Group type: COMPARATOR
Intervention: Apollo progressive addition lenses (PALs)
Number of subjects: 600
Study: 34648182

Group type: EXPERIMENTAL
Intervention: Pro-social messaging recruitment letters
Number of subjects: 15835

Group type: COMPARATOR
Intervention: Financial reimbursement messaging
Number of subjects: 15835

Group type: EXPERIMENTAL
Intervention: Pro-social messaging combined with financial reimbursement
Number of subjects: 15835

Group type: COMPARATOR
Intervention: Control group (no pro-social or financial messaging)
Number of subjects: 15835
Study: 32156544

Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 mg/kg bolus followed by 2 mg/kg/h continuous infusion)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (saline solution)
Number of subjects: 48
Study: 34226291

Group type: EXPERIMENTAL
Intervention: Comprehensive pelvic and para‐aortic lymphadenectomy
Number of subjects: 640

Group type: COMPARATOR
Intervention: Total hysterectomy plus bilateral salpingo‐oophorectomy
Number of subjects: 640
Study: 32865108

Group type: EXPERIMENTAL
Intervention: Hypothetical telemedicine service
Number of subjects: 203

Group type: COMPARATOR
Intervention: Telemedicine status quo scheme
Number of subjects: 203
Study: 35608639

Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 33435941

Group type: EXPERIMENTAL
Intervention: EET (ergonomic and exercise training)
Number of subjects: 740

Group type: COMPARATOR
Intervention: EHP (ergonomic and health promotion)
Number of subjects: 740
Study: 33902498

Group type: EXPERIMENTAL
Intervention: MRI based staging (arm A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard surgical staging with or without laparoscopy (arm B)
Number of subjects: 0
Study: 32372588

Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SCIT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subcutaneous immunotherapy (SCIT) and Sublingual immunotherapy (SLIT)
Number of subjects: 0
Study: 35657850

Group type: EXPERIMENTAL
Intervention: Influenza+BCG
Number of subjects: 2615

Group type: COMPARATOR
Intervention: Influenza
Number of subjects: 2615
Study: 34648847

Group type: EXPERIMENTAL
Intervention: Aerobic training (AT)
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Combined training (CT)
Number of subjects: 388

Group type: COMPARATOR
Intervention: Education class (Control)
Number of subjects: 388
Study: 32961507

Group type: EXPERIMENTAL
Intervention: Psychosocial stress with work interruptions
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Psychosocial stress without work interruptions
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control condition (no psychosocial stress)
Number of subjects: 90
Study: 34024814

Group type: EXPERIMENTAL
Intervention: Short foot exercise group (SFEG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (ConG)
Number of subjects: 30
Study: 35570699

Group type: EXPERIMENTAL
Intervention: Oral SDX (120 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral SDX (240 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IN SDX (80 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IV SDX (30 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: IV SDX
Number of subjects: 0

Group type: COMPARATOR
Intervention: d-MPH (80 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: d-MPH (40 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: d-MPH (15 mg)
Number of subjects: 0
Study: 33025052

Group type: EXPERIMENTAL
Intervention: Episealer implant
Number of subjects: 80
Study: 32131748

Group type: EXPERIMENTAL
Intervention: Minimalist shoes
Number of subjects: 64
Study: 36316692

Group type: EXPERIMENTAL
Intervention: Low pre-RRT penKid levels (penKid ≤ 89 pmol/l)
Number of subjects: 210

Group type: COMPARATOR
Intervention: High pre-RRT penKid levels
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Low pre-RRT penKid levels (penKid ≤ 89 pmol/l) at day 3 of RRT
Number of subjects: 210

Group type: COMPARATOR
Intervention: High pre-RRT penKid levels at day 3 of RRT
Number of subjects: 210
Study: 33308273

Group type: EXPERIMENTAL
Intervention: Arabic version of the Hayling Sentence Completion Test (HSCT) - Automatic condition
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Arabic version of the Hayling Sentence Completion Test (HSCT) - Inhibition condition
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Electricity as a heating method
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Higher problematic mobile phone use
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Wood as a heating system
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Arabian incense (bakhour) as a heating method
Number of subjects: 350
Study: 36409018

Group type: EXPERIMENTAL
Intervention: Duloxetine (30 mg, doubled if no response at 2 weeks)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 82
Study: 34138850

Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 53787

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 53787

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 53787

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 53787

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 53787

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin
Number of subjects: 53787

Group type: EXPERIMENTAL
Intervention: Ximelagatran
Number of subjects: 53787

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 53787

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 53787

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53787
Study: 32326953

Group type: EXPERIMENTAL
Intervention: NIRS monitoring training module
Number of subjects: 100
Study: 35363502

Group type: EXPERIMENTAL
Intervention: Individualized exercise oncology program (12 weeks, aligned with ACSM guidelines)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Control group (standard of care, resource guide)
Number of subjects: 243
Study: 34091047

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 32996010

Group type: EXPERIMENTAL
Intervention: D-Mg2+ at 0.75 mmol/L
Number of subjects: 39
Study: 34410042

Group type: COMPARATOR
Intervention: LY2963016 (LY IGlar)
Number of subjects: 58